<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203681</url>
  </required_header>
  <id_info>
    <org_study_id>20170462</org_study_id>
    <nct_id>NCT03203681</nct_id>
  </id_info>
  <brief_title>Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters</brief_title>
  <official_title>Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acerus Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low testosterone affects more than 10% of men worldwide, with high incidence in the&#xD;
      elderly.This will be a prospective case study. The investigators will identify men with&#xD;
      hypogonadism in our clinic interested in Natesto for testosterone replacement therapy (TRT).&#xD;
      Natesto is a relatively new form of testosterone replacement therapy that is delivered&#xD;
      intranasal to men diagnosed with low testosterone. Current advantages to Natesto include ease&#xD;
      of delivery and decreased risk of transference. Recently Natesto 4.5% (125 uL/nostril, 11.0mg&#xD;
      testosterone/dose), three times a day (TID) dosing was shown to also increase serum&#xD;
      testosterone while maintaining normal, though decreased, serum levels of Luteinizing Hormone&#xD;
      (LH) and Follicle-Stimulating Hormone(FSH). 40 participants will be enrolled and receive&#xD;
      treatment with Natesto.The study will identify men with confirmed hypogonadism (testosterone&#xD;
      (T) &lt;350 on 2 consecutive Testosterone samples collected greater than 1.5 hours apart between&#xD;
      6am and 10am with demonstrated symptoms of hypogonadism). Participants with a history of&#xD;
      prostate cancer, testis cancer, azoospermia, or genetic cause of hypogonadism will be&#xD;
      excluded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low testosterone affects more than 10% of men worldwide, with high incidence in the elderly).&#xD;
      While Natesto has been shown to have positive effects on Testosterone while maintaining LH&#xD;
      and FSH, the impact on sperm count has not yet been proven.&#xD;
&#xD;
      Study Design and Duration of Treatment: Participants will take Natesto 11g intra nasally&#xD;
      there times a day (TID) for 16 weeks (120 days) between serum and semen evaluations.&#xD;
&#xD;
      Subject Population: The study will identify men with confirmed hypogonadism (testosterone (T)&#xD;
      &lt;350 on 2 consecutive Testosterone samples collected greater than 1.5 hours apart between 6am&#xD;
      and 10am with demonstrated symptoms of hypogonadism). Subjects with a history of prostate&#xD;
      cancer, testis cancer, azoospermia, or genetic cause of hypogonadism will be excluded.&#xD;
&#xD;
      Number of subjects: 40 participants will be enrolled and receive treatment with Natesto.&#xD;
&#xD;
      Study Duration:Total participation in the study will be approximately 24-28 weeks.&#xD;
&#xD;
      Study Procedures: Participants will undergo a total of six study visits. At the first visit,&#xD;
      subjects will undergo screening procedures which will include signing of the consent form,&#xD;
      physical exam, assessment for inclusion and exclusion criteria, Sexual Health Inventory in&#xD;
      Men (SHIM) and quality of life questionnaire, blood sample for clinical laboratory&#xD;
      assessment, and a semen analysis. At visit 2, subjects will undergo a second semen analysis&#xD;
      and blood analysis for T. After 12 weeks (90 days), Participants will return for a third&#xD;
      visit for blood sample and semen analysis as well as safety monitoring. The Participants will&#xD;
      also be given SHIM and quality of life questionnaires. This procedure will be repeated at&#xD;
      week 24 to get a final blood and semen analysis.&#xD;
&#xD;
      Study Endpoints: The primary endpoint will be change in FSH, LH, Estradiol, T, and Semen&#xD;
      Analysis after 12 weeks and 24 weeks of treatment with Natesto. The secondary endpoint will&#xD;
      be monitoring for adverse events&#xD;
&#xD;
      Statistical Methods: Analyses will consist of summaries of the values and total change from&#xD;
      baseline in each value (visit value versus baseline value) using descriptive statistics&#xD;
      (sample size, mean, median, standard deviation, 95% confidence interval, minimum, and&#xD;
      maximum). The change from baseline in each endpoint will compared using a two-sample t-test,&#xD;
      or the Wilcoxon rank sum test if distributional assumptions are violated. The primary time&#xD;
      point of interest for assessing hormone effects is the week 12 visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2017</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Testosterone Levels From Baseline to 27 Weeks</measure>
    <time_frame>Baseline, 27 Weeks</time_frame>
    <description>Testosterone levels measured in ng/dL analyzed from peripheral venous puncture blood draw</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Estradiol Levels From Baseline to 27 Weeks</measure>
    <time_frame>Baseline, 27 Weeks</time_frame>
    <description>Estradiol levels measured in pg/mL analyzed from peripheral venous puncture blood draw</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Gonadotropin Levels From Baseline to 27 Weeks</measure>
    <time_frame>Baseline, 27 Weeks</time_frame>
    <description>Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) levels, both measured in mIU/mL analyzed from peripheral venous puncture blood draw</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Increase in SF-36 QOL Scores From Baseline</measure>
    <time_frame>27 Weeks</time_frame>
    <description>The number of participants with an increase of at least 1 point from their SF-36 QOL scores from baseline will be reported. Short Form-36 (SF-36) Quality of Life (QOL) questionnaire has a proprietary scoring system that ranges from 1-5 and each domain is individually assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Sperm Counts From Baseline to 27 Weeks</measure>
    <time_frame>Baseline, 27 Weeks</time_frame>
    <description>Sperm count measured in million sperm/mL analyzed from semen sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>27 Weeks</time_frame>
    <description>Incidence of adverse events as assessed per treating physician</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypogonadism, Male</condition>
  <arm_group>
    <arm_group_label>Natesto</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natesto</intervention_name>
    <description>4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.</description>
    <arm_group_label>Natesto</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily sign and date the study consent form(s) which have been approved by an&#xD;
             Institutional Review Board (IRB). Written consent must be obtained prior to the&#xD;
             initiation of any study procedures.&#xD;
&#xD;
          -  Male between 18 and 55 years of age, inclusive, with documented onset of hypogonadism&#xD;
             prior to age 55.&#xD;
&#xD;
          -  Documented diagnosis of primary hypogonadism (congenital or acquired) or&#xD;
             hypogonadotropic hypogonadism (congenital or acquired).&#xD;
&#xD;
          -  Serum total testosterone &lt; 350 ng/dL based on 2 consecutive blood samples obtained at&#xD;
             least 1.5 hours apart between 6:00 am and 10:00 am following an appropriate washout of&#xD;
             current androgen replacement therapy.&#xD;
&#xD;
          -  Na√Øve to androgen replacement or has discontinued current treatment and completed a&#xD;
             washout of 4 weeks following androgen treatment (excluding Testopel). Washout must be&#xD;
             completed prior to collection of baseline serum testosterone samples to determine&#xD;
             study eligibility.&#xD;
&#xD;
          -  Judged to be in good general health as determined by the principal investigator based&#xD;
             upon the results of a medical history, physical examination, vital signs, laboratory&#xD;
             profile and a 12-lead electrocardiogram (ECG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of significant sensitivity or allergy to androgens, castor oil or product&#xD;
             excipients.&#xD;
&#xD;
          -  Clinically significant findings in the prestudy examinations including abnormal breast&#xD;
             examination requiring follow-up, abnormal ECG.&#xD;
&#xD;
          -  Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or&#xD;
             International Prostate Symptoms Score (I-PSS) &gt; 19 points.&#xD;
&#xD;
          -  Body mass index (BMI) ‚â• 30 kg/m2.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory value, in the opinion of the investigator,&#xD;
             in serum chemistry, hematology, or urinalysis including but not limited to:&#xD;
&#xD;
               1. Baseline hemoglobin &lt; 11.5 g/dL or &gt; 16 g/dL&#xD;
&#xD;
               2. Hematocrit &lt; 35% or &gt; 54%&#xD;
&#xD;
               3. Serum transaminases &gt; 2.5 times upper limit of normal&#xD;
&#xD;
               4. Serum bilirubin &gt; 2.0 mg/dL&#xD;
&#xD;
               5. Creatinine &gt; 2.0 mg/dL f. Prostate-Specific Antigen (PSA) &gt; 2 ng/mL&#xD;
&#xD;
          -  History of seizures or convulsions, including febrile, alcohol or drug withdrawal&#xD;
             seizures.&#xD;
&#xD;
          -  History of any clinically significant illness, infection, or surgical procedure within&#xD;
             4 weeks prior to study drug administration.&#xD;
&#xD;
          -  History of stroke or myocardial infarction within the past 5 years.&#xD;
&#xD;
          -  History of, or current or suspected, prostate or breast cancer.&#xD;
&#xD;
          -  History of diagnosed, severe, untreated, obstructive sleep apnea.&#xD;
&#xD;
          -  History of abuse of alcohol or any drug substance in the opinion of the investigator&#xD;
             within the previous 2 years.&#xD;
&#xD;
          -  Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt&#xD;
             of a transfusion of any blood product within 12 weeks prior to the start of treatment.&#xD;
&#xD;
          -  Inadequate venous access for collection of serial blood samples required for&#xD;
             pharmacokinetic profiles.&#xD;
&#xD;
          -  Receipt of any investigational product within 4 weeks or within 5 half-lives prior to&#xD;
             the start of treatment.&#xD;
&#xD;
          -  Inability to understand and provide written informed consent for the study.&#xD;
&#xD;
          -  Considered by the investigator or the sponsor-designated physician, for any reason,&#xD;
             that the subject is an unsuitable candidate to receive Natesto.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjith Ramasamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Amory JK, Anawalt BD, Blaskovich PD, Gilchriest J, Nuwayser ES, Matsumoto AM. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. J Androl. 2002 Jan-Feb;23(1):84-91.</citation>
    <PMID>11780927</PMID>
  </reference>
  <reference>
    <citation>Haring R, Ittermann T, V√∂lzke H, Krebs A, Zygmunt M, Felix SB, Grabe HJ, Nauck M, Wallaschofski H. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania. Aging Male. 2010 Dec;13(4):247-57. doi: 10.3109/13685538.2010.487553. Epub 2010 May 26.</citation>
    <PMID>20504090</PMID>
  </reference>
  <reference>
    <citation>Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016 Apr;117(4):677-85. doi: 10.1111/bju.13337. Epub 2015 Oct 23.</citation>
    <PMID>26496621</PMID>
  </reference>
  <reference>
    <citation>Ullah MI, Riche DM, Koch CA. Transdermal testosterone replacement therapy in men. Drug Des Devel Ther. 2014 Jan 9;8:101-12. doi: 10.2147/DDDT.S43475. eCollection 2014. Review.</citation>
    <PMID>24470750</PMID>
  </reference>
  <reference>
    <citation>Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004 Jan 29;350(5):482-92. Review.</citation>
    <PMID>14749457</PMID>
  </reference>
  <reference>
    <citation>Rogol AD, Tkachenko N, Bryson N. Natesto‚Ñ¢ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology. 2016 Jan;4(1):46-54. doi: 10.1111/andr.12137. Epub 2015 Dec 22. Erratum in: Andrology. 2017 Jul;5(4):844.</citation>
    <PMID>26695758</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <results_first_submitted>June 13, 2021</results_first_submitted>
  <results_first_submitted_qc>July 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Ranjith Ramasamy, MD</investigator_full_name>
    <investigator_title>Director of Male Reproductive Medicine and Surgery/Assistant professor in Department of Urology at University of Miami</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03203681/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Natesto</title>
          <description>Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.&#xD;
Natesto: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Month</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Months</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Natesto</title>
          <description>Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.&#xD;
Natesto: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Demographics</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Testosterone Levels From Baseline to 27 Weeks</title>
        <description>Testosterone levels measured in ng/dL analyzed from peripheral venous puncture blood draw</description>
        <time_frame>Baseline, 27 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natesto</title>
            <description>Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.&#xD;
Natesto: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Testosterone Levels From Baseline to 27 Weeks</title>
          <description>Testosterone levels measured in ng/dL analyzed from peripheral venous puncture blood draw</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="652" spread="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Estradiol Levels From Baseline to 27 Weeks</title>
        <description>Estradiol levels measured in pg/mL analyzed from peripheral venous puncture blood draw</description>
        <time_frame>Baseline, 27 Weeks</time_frame>
        <population>Estradiol levels were not collected for all participants that completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Natesto</title>
            <description>Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.&#xD;
Natesto: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estradiol Levels From Baseline to 27 Weeks</title>
          <description>Estradiol levels measured in pg/mL analyzed from peripheral venous puncture blood draw</description>
          <population>Estradiol levels were not collected for all participants that completed the study</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Gonadotropin Levels From Baseline to 27 Weeks</title>
        <description>Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) levels, both measured in mIU/mL analyzed from peripheral venous puncture blood draw</description>
        <time_frame>Baseline, 27 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natesto</title>
            <description>Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.&#xD;
Natesto: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gonadotropin Levels From Baseline to 27 Weeks</title>
          <description>Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) levels, both measured in mIU/mL analyzed from peripheral venous puncture blood draw</description>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Luteinizing Hormone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Increase in SF-36 QOL Scores From Baseline</title>
        <description>The number of participants with an increase of at least 1 point from their SF-36 QOL scores from baseline will be reported. Short Form-36 (SF-36) Quality of Life (QOL) questionnaire has a proprietary scoring system that ranges from 1-5 and each domain is individually assessed</description>
        <time_frame>27 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natesto</title>
            <description>Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.&#xD;
Natesto: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Increase in SF-36 QOL Scores From Baseline</title>
          <description>The number of participants with an increase of at least 1 point from their SF-36 QOL scores from baseline will be reported. Short Form-36 (SF-36) Quality of Life (QOL) questionnaire has a proprietary scoring system that ranges from 1-5 and each domain is individually assessed</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Sperm Counts From Baseline to 27 Weeks</title>
        <description>Sperm count measured in million sperm/mL analyzed from semen sample</description>
        <time_frame>Baseline, 27 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natesto</title>
            <description>Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.&#xD;
Natesto: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sperm Counts From Baseline to 27 Weeks</title>
          <description>Sperm count measured in million sperm/mL analyzed from semen sample</description>
          <units>million sperm/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events</title>
        <description>Incidence of adverse events as assessed per treating physician</description>
        <time_frame>27 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natesto</title>
            <description>Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.&#xD;
Natesto: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Incidence of adverse events as assessed per treating physician</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Azoospermia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Oligospermia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epistaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Natesto</title>
          <description>Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.&#xD;
Natesto: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Azoospermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Severe Oligospermia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Nasal Irritation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ranjith Ramasamy</name_or_title>
      <organization>University of Miami</organization>
      <phone>3052433670</phone>
      <email>ramasamy@miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

